I’d call ‘enthusiasm for MDR’, keeping a close eye on my investment.
Never fall in love with a stock and all that, but I’ve made the mistake of not paying attention to the company and industry that I’ve lost out on significant paper profits elsewhere.
MDR is my largest holding, by a lot, so I’m overweight here. Was holding a couple million before consolidation, now a few hundred thousand.
I’m trusting of Management. They’re not hiring mates, cronies or stooges and believe they’re honestly aiming for a large international footprint and a MC in the multiples of where we are now.
I’m mindful of the freebies and options. If they were doing this without a rising share price then it could be seen as lining their own pockets. As the share price has been rising, then I’m happy to go along for the ride. I’m also cautious of long delays and everything being classified as ‘imminent’. As long as every quarter they can deliver services and publish revenue numbers (Adheris - $825k) and additional news that will deliver new revenue (HMS) then I’ll continue to ride the coat tails.
They are heavily vested themselves. Top 20 hold 75%. The peers are nowhere near that. I’ve not seen a single share sold by any of them for ‘taxation or divestment purposes’, which suggests the top hasn’t been hit yet. Non-delivery or dilutionary deals reduces their own balance. I think the last CR of $17M in October when I recall the MC only being $60M was very clever. There’s still $16M there which will take many quarters to consume.
My other thought was, could money from the peers who are dropping share price and MC be flowing into MedAdvisor?
Add to My Watchlist
What is My Watchlist?
